Key Market Indicator:
Welcome our new Research Provider
In the Research & Ratings section, you can access assessments from renowned analyst firms that specialize in the due diligence and valuation of companies that are generally listed on the stock exchange. Starting from the research reports, you can access further research tools and information with just a few mouse clicks, which offer you additional options for obtaining and assessing information.
Tue, 09.11.2021
SYZYGY AG
9 months 2021: Turnaround successful; revenue and earnings development 'in
line'; forecasts, estimates and target price confirmed
Based on the first nine months of 2021, Syzygy AG's sales revenues of EUR
44.66 million (previous year: EUR 40.69 million) were 9.8 % above the
previous year's level and thus in line with our expectations. Although th [ … ]
Tue, 09.11.2021
Bitcoin Group SE
Highly profitable trading platform for cryptocurrency exceeds 1 million
customers and continues to grow. The business model is relatively
independent of the crypto price.
Bitcoin Group SE, as the holding company, primarily operates the crypto
trading site bitcoin.de. The trading platform is highly profitable and is
experiencing dynamic growth. F [ … ]
Mon, 08.11.2021
The NAGA Group AG
Stronger focus on customer growth, financial flexibility through capital
increase, forecasts raised, target price: EUR11.70
As expected, The NAGA Group AG (NAGA for short) has been able to continue
its impressive growth course in 2021. This is evident from both the
published half-year report 2021 and the preliminary figures for the third
quarter [ … ]
Mon, 18.10.2021
MagForce AG
FDA announces conditions for the final pivotal study; study
expected to start in 2021 and to be completed in mid-2022; timeframe
largely in line with our expectations; forecasts, price target and BUY
rating confirmed
According to corporate news of 13.10.2021, MagForce AG has made significant
progress in obtaining approval for the treatment of pr [ … ]
Tue, 12.10.2021
Saturn Oil & Gas Inc.
Upcoming Investor Event:
Saturn Oil & Gas to present at digital International Investment Forum (IIF)
On October 14, the IIF International Investment Forum will take place. At
this forum, Saturn Oil & Gas Inc. will also present its business model and
current business development.
Presentation slot:
Saturn Oil & Gas Inc.
11.15 am E [ … ]
Mon, 11.10.2021
Cardiol Therapeutics
Upcoming Investor Event:
Cardiol Therapeutics to present at digital International Investment Forum
(IIF)
On October 14, the IIF International Investment Forum will take place. At
this fo-rum, Cardiol Therapeutics will also present its business model and
current business development.
Presentation slot:
Cardiol Therapeutics Inc.
09.00 am EDT*
[ … ]
Mon, 04.10.2021
Coreo AG
1H 2021: earnings improvement due to higher rental income and sale of
properties; slight increase in 2021 forecasts; price target and rating
confirmed
As we expected, Coreo AG increased rental income to EUR1.93 million in the
first six months of 2021 (previous year: EUR1.55 million). The increase in
rental income is primarily attributable to the [ … ]
Mon, 27.09.2021
UmweltBank AG
H1 2021: Business volume significantly increased, forecasts and target
price slightly raised, rating reduced to HOLD after strong share price
performance
The increase in business volume, i.e. total assets plus contingent
liabilities and other obligations, forecast by the Umweltbank management
was impressively confirmed with the presentation of t [ … ]
Mon, 20.09.2021
wallstreet:online AG
HY1 2021: Continuation of dynamic customer and revenue growth; Significant
profitability increase expected in HY2; GBC estimates and price target
confirmed
Sales development HY1 2021
wallstreet:online AG (wallstreet:online) was able to continue its dynamic
growth course in the first six months of the current financial year.
Compared to the sam [ … ]
Mon, 13.09.2021
Cardiol Therapeutics Inc.
Die FDA hat die Freigabe zur Durchführung der klinischen Phase-II-Studie
für CardiolRX(TM) bei akute Myokarditis erteilt.
Dr. Guillermo Torre-Amione wurde zum neuen Vorsitzenden ernannt
Die Aktien der Cardiol Therapeutics sind nun auch an der NASDAQ gelistet.
Am 24. August erhielt Cardiol Therapeutics von der FDA die Freigabe des
IND-A [ … ]
